A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2019
Price : $35 *
At a glance
- Drugs NV-5138 (Primary)
- Indications Depressive disorders
- Focus Adverse reactions
- Sponsors Navitor Pharmaceuticals
- 12 Sep 2019 According to a Navitor Pharmaceuticals media release, the company plans to present additional data from the Phase 1 program (three studies 001, 002, 003) at upcoming medical meetings this fall.
- 12 Sep 2019 Results presented in a Navitor Pharmaceuticals media release.
- 07 Jul 2019 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History